Sector News

ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor

March 5, 2015
Life sciences
(GLOBE NEWSWIRE) – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of vitreo-retinal diseases, is pleased to announce that Joseph Markoff, Ph.D., M.D. has joined the Company as Scientific Advisor. Dr. Markoff will report to Paul G. Howes, Executive Chairman of ThromboGenics Inc., and work with the Medical Affairs team in the U.S. and the global Clinical Development team.
 
Dr. Markoff has over 35 years of experience as an ophthalmic surgeon at the Wills Eye Hospital in Philadelphia, PA. He has directed the hospital’s Visual Physiology service for the past 32 years and also holds the rank of Attending Surgeon and Clinical Professor of Ophthalmology at Thomas Jefferson University Medical School.
 
Dr. Markoff founded Philadelphia Eye Associates, a leading private eye care practice in the Philadelphia area. From February 2010 till recently, he assumed the role as Global Director for Scientific Affairs in Ophthalmology at Merck & Co., Inc.
 
Dr. Markoff has conducted over 50 clinical trials during his career sponsored by companies such as Alcon, Allergan, Pfizer, Pharmacia and Merck & Co.
 
Paul Howes, Executive Chairman of ThromboGenics, Inc. said: “Joseph Markoff adds vast experience and knowledge in ophthalmology, particularly in the retinal space, to the ThromboGenics team. I expect his expertise to prove hugely valuable as we roll-out the results of on-going real-world clinical studies on treatment of symptomatic VMA with JETREA® and embark on new indications such as diabetic retinopathy.”
 
Source: ThromboGenics

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.